Revenue ($USD) : $7,394,200,000
R&D spend : $458,700,000
Employees : 18,000
Fiscal year end : 12/31/2023
CEO : Ivan Tornos

www.zimmerbiomet.com

Zimmer Biomet continues to expand its orthopedic surgical robotics and digital surgery offerings to boost its competitiveness against rivals such as Stryker and Johnson & Johnson’s DePuy Synthes. In June, ZB announced a limited distribution agreement with Think Surgical for Think’s wireless, handheld TMINI miniature robotic system for total knee arthroplasty (TKA). Zimmer Biomet officials see TMINI complementing its flagship Rosa surgical robot portfolio with a handheld robotic option. Earlier in 2024, the FDA cleared the Rosa Shoulder robotic surgery system, making it the fourth application for ZB’s Rosa. On the M&A front, Zimmer Biomet recently announced a deal to acquire OrthoGrid Systems and its AI-driven surgical guidance systems for total hip replacement. –CN